Scott R MacKenzie Foundation Report issue

Foundation Phase 4

Organization Overview

First Clinical Trial
2018
NCT03489863
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Scott R MacKenzie Foundation

Active Ingredients

Drugs in Phase 4 Trials (3)

cangrelor (kengreal) (2 trials)

prasugrel (effient) (2 trials)

ticagrelor (brilinta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Myocardial Ischemia (Phase 4)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 3